BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Symbol: NASDAQ:BLTI
- CUSIP: N/A
- Web: www.biolase.com/
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Net Margins: -34.01%
- Return on Equity: -151.86%
- Return on Assets: -43.37%
Frequently Asked Questions for BIOLASE (NASDAQ:BLTI)
What is BIOLASE's stock symbol?
BIOLASE trades on the NASDAQ under the ticker symbol "BLTI."
Who are some of BIOLASE's key competitors?
Some companies that are related to BIOLASE include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Boston Scientific Corporation (BSX), Koninklijke Philips N.V. (PHG), Intuitive Surgical (ISRG), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR) and Quidel Corporation (QDEL).
Who are BIOLASE's key executives?
BIOLASE's management team includes the folowing people:
- Paul N. Clark, Independent Chairman of the Board
- Harold C. Flynn Jr., President, Chief Executive Officer
- Brendan O'Connell, Vice President - Finance and Corporate Controller
- Holger Arens, Vice President, Managing Director of Europe, the Middle East and Africa
- James D. Surek, Vice President - Sales, Americas
- Michael Roux, Vice President of Marketing
- Matthew Wilson, Vice President of Human Resources
- Samuel B. Low, Vice President - Dental and Clinical Affairs, Chief Dental Officer
- George W. Bickerstaff III, Director
- Tamar D. Howson, Director
How do I buy BIOLASE stock?
Shares of BIOLASE can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIOLASE's stock price today?
MarketBeat Community Rating for BIOLASE (NASDAQ BLTI)MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of BIOLASE stock can currently be purchased for approximately $2.42.
Consensus Ratings for BIOLASE (NASDAQ:BLTI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for BIOLASE (NASDAQ:BLTI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for BIOLASE (NASDAQ:BLTI)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for BIOLASE (NASDAQ:BLTI)
Current Year EPS Consensus Estimate: $-0.43 EPS
Dividend History for BIOLASE (NASDAQ:BLTI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for BIOLASE (NASDAQ:BLTI)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for BIOLASE (NASDAQ:BLTI)
Latest Headlines for BIOLASE (NASDAQ:BLTI)
BIOLASE (BLTI) Chart for Friday, September, 22, 2017